Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.41 |
| ▸ | PRKX | P51817 | 3/20 | 0.41 |
| ▸ | PRKACA | P17612 | 5/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.38 |
| ▸ | PRKACG | P22612 | 4/20 | 0.38 |
| ▸ | PRKACB | P22694 | 4/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | PRKCG | P05129 | 3/20 | 0.38 |
| ▸ | PRKCB | P05771 | 3/20 | 0.38 |
| ▸ | PRKCA | P17252 | 3/20 | 0.38 |
| ▸ | PRKCH | P24723 | 3/20 | 0.38 |
| ▸ | PRKCI | P41743 | 3/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438695 | 1.00 | ROCK1 (0.41) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL23795358 | 1.00 | ROCK1 (0.41) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL30439350 | 0.89 | ROCK1 (0.42) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL30439456 | 0.89 | ROCK1 (0.42) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL23795330 | 0.89 | ROCK1 (0.42) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL23795312 | 0.89 | ROCK1 (0.42) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL30439464 | 0.88 | ROCK1 (0.45) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL23795370 | 0.88 | ROCK1 (0.45) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL23795372 | 0.88 | ROCK1 (0.45) | ROCK1PRKCDROCK2PRKCEPRKD1 | |
| SCHEMBL30439073 | 0.88 | ROCK1 (0.45) | ROCK1PRKCDROCK2PRKCEPRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2025-04-01 | — | — | US | claimed |
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2025-04-01 | — | — | US | disclosed |
| CN-111116555-B | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3878846-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| EP-3878846-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-111116555-A | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2020-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | ROCK1, RHOA, ROCK2 | ROCK1 1/4885PRKCD 517/4885ROCK2 3/4885 |
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | ROCK1, RHOA, ROCK2 | ROCK1 1/4885PRKCD 517/4885ROCK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.